Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program

E. Anders Kolb, Richard Gorlick, Stephen T. Keir, John M. Maris, Min H. Kang, C. Patrick Reynolds, Richard B. Lock, Hernan Carol, Jianrong Wu, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

BAL101553 is a highly water soluble prodrug of BAL27862 that arrests tumor cell proliferation and induces cell death in cancer cells through disruption of the microtubule network. In vitro BAL27862 demonstrated potent activity, with the median relative IC50 (rIC50) of 13.8nM (range 5.4-25.2nM). The in vitro activity of BAL27862 against the PPTP cell lines is distinctive from that previously described for vincristine. BAL101553 induced significant differences in EFS distribution compared to control in 16 of 30 (53%) solid tumor xenografts and in two of four (67%) of the evaluable ALL xenografts. No objective responses were observed.

Original languageEnglish (US)
Pages (from-to)1106-1109
Number of pages4
JournalPediatric Blood and Cancer
Volume62
Issue number6
DOIs
StatePublished - Jun 1 2015

    Fingerprint

Keywords

  • Developmental therapeutics
  • Microtubule-binding agents
  • Preclinical testing
  • Vascular-disrupting agents

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

Kolb, E. A., Gorlick, R., Keir, S. T., Maris, J. M., Kang, M. H., Reynolds, C. P., Lock, R. B., Carol, H., Wu, J., Kurmasheva, R. T., Houghton, P. J., & Smith, M. A. (2015). Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 62(6), 1106-1109. https://doi.org/10.1002/pbc.25329